Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with advanced portal vein tumor thrombus 

Contexts in source publication

Context 1

... using cisplatin (CDDP) and 5-fluorouracil (5-FU) as key drugs, as well as regimens using 5-FU and interferon (IFN) as key drugs, have been used in many of the reported cases for which hepatic arterial infusion chemotherapy using a port-catheter system was employed. Using low-dose 5-FU plus CDDP (LFP) for Vp3/ Vp4 HCC, Ando et al. 27 (Table 2) reported a response rate of 48% and an MST of 10.2 months. The most common adverse events were nausea and loss of appetite, and these were con- trollable with medical treatment. ...

Context 2

... did report that malfunction of the port-catheter system and/ or its implantation accounted for more than 20% of the com- plications. Obi et al. 28 (Table 2) reported that the outcomes of IFN and 5-FU combination therapy for Vp3/Vp4 HCC were a response rate of 52.6%, an MST of 6.9 months, and a 1-year survival rate of 34%. The majority of adverse events were negligible, while depression caused by IFN was the only adverse event of grade 3 or higher, which occurred in a patient for whom the treatment was discontinued. ...

Context 3

... regard to the one-shot intra-arterial infusion, we found some reports regarding intra-arterial CDDP infusion. Ikeda et al. 29 (Table 2) reported that the outcomes of their phase II prospective trial of intra-arterial CDDP infusion for Vp3/Vp4 HCC were a response rate of 28% and an MST of 7.1 months. Regarding adverse events of grade 3 or higher, decreased blood cells and transient increases in transami- nases were seen but required no special treatment. ...